Siemens Healthineers' Accela Radiotherapy Bet: A 60-Second Treatment That Won't Reach Patients Until 2027

Siemens Healthineers showcased its Accela radiotherapy platform in Boston, sending shares higher, but FDA 510(k) clearance is still pending.

Siemens Healthineers used the ASTRO annual meeting in Boston to pull back the curtain on Accela, a radiotherapy system built on its NeoArc and DMAT architecture — a platform the company says took roughly eight years to develop. The pitch is straightforward: stereotactic body treatments across multiple tumor sites delivered in as little as 60 seconds, fast enough in theory to be completed within a single breath-hold.

That claim landed well with investors. The DAX-listed medtech group's shares climbed 3.5% on Monday to close at EUR 39.13, with the broader medical technology sector also enjoying a firm start to the week, buoyed by the US industry gathering. By Tuesday the stock was trading 3.6% higher at EUR 39.17.

Why Varian's Road Back Runs Through Boston

Radiation therapy, housed within the group's Varian subsidiary, sits among the core growth engines for the Erlangen-based company. Shorter irradiation windows free up treatment capacity inside clinics while easing the physical burden on patients — a combination that reliably draws market attention whenever it advances.

For Varian specifically, the Accela launch reads as something of a turning point. After years of development work, the unit now has to convert its technological lead into revenue. Partner support is already taking shape: Sun Nuclear reported that it has validated its AdaptCHECK quality assurance software for the new platform, covering patient-specific dose verification and secondary calculations. The two systems are designed to work in tandem so clinics can run a smooth workflow.

The Regulatory Gate That Matters Most

None of that changes a hard fact: Accela is not yet commercially available in any market. Siemens Healthineers is working through the US Food and Drug Administration's 510(k) clearance process, and until that green light arrives, no orders can ship. Early pre-orders are tied directly to regulatory approval.

That makes the filing the single most important variable for the investment case. Hospitals treat these machines as major capital commitments, and investment decisions in radiation oncology demand dependable timelines. When approval slips, clinics have a long track record of pushing orders back. The 510(k) review also carries the ever-present risk of unexpected additional data requests, which would inevitably delay the commercial launch.

The Efficiency Math Behind the Bull Case

Should clearance arrive on schedule, the recovery potential is clear. Accela's technical specifications target the bottlenecks that plague modern cancer centers: gantry speeds of up to 2.5 rotations per minute and dose rates peaking at 40 Gray per minute. Combined, those figures slash treatment times dramatically, letting centers push far more patients through each treatment day. Higher throughput lowers the cost per case — a powerful economic argument for clinic administrators weighing a switch.

Jefferies analyst Julien Dormois rates the stock a Buy with a EUR 50 price target, calling Accela a quantum leap in speed, precision and work efficiency. In his view, that edge could allow Varian to capture meaningful market share from competitors, a thesis reinforced by broad partner backing such as the Sun Nuclear tie-up.

Patience Is the Price of Admission

The counterweight is timing. Dormois cautions against premature revenue expectations, stressing that the impact on the profit and loss statement will build gradually rather than in one step. Meaningful top-line contribution isn't expected until fiscal 2027 and 2028, according to media reports.

That pattern is familiar in medtech capital equipment. Clinical milestones strengthen a market position, but lengthy hospital procurement cycles mean the financial payoff arrives late. Clinics often plan radiotherapy budgets years in advance, and replacement purchases require drawn-out approvals from hospital committees. If health systems trim spending amid tight budgets, the rollout slows further — leaving eight years of development effort facing hesitant demand.

A Second Analyst Voice, and a Wider Technology Push

Jefferies isn't alone in its optimism. RBC Capital Markets kept its Outperform rating on Siemens Healthineers on September 22 with a EUR 45 target, reflecting continued confidence in the group's strategic direction.

Beyond radiation therapy, the company is also driving adoption of advanced imaging. RHÖN-KLINIKUM Campus Bad Neustadt has begun using the NAEOTOM Alpha.Peak photon-counting CT for diagnostics, including precise detection of stenoses and aneurysms, the company said Thursday. Deployments at specialized centers carry strategic weight, demonstrating that the new sensor technology works in day-to-day clinical practice. That manufacturing base came into focus roughly three weeks ago when Siemens Healthineers opened its sensor plant in Forchheim.

Hard numbers on current trading arrive soon. On November 5, the company publishes fourth-quarter results and walks analysts through them at a conference call. Until then, the share price will likely take its cues from the FDA — the official conclusion of the 510(k) review is the next real catalyst, and only with that milestone does the actual commercial cycle begin.